Tender is the day

7 June 2007 By Rob Cox

For years, confusion over the best price rule kept this fast and efficient takeover tool virtually off limits. SEC reforms changed that. As the $11.4bn Biomet deal shows, this can expedite deals and get round pesky proxy advisors. So is this good or bad for investors?

This content is for Subscribers only

To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)